Stage I seminoma: Adjuvant treatment is effective but is it necessary?

Journal of the National Cancer Institute

Volumn 103, Issue 3, 2011, Pages 194-196

  Chung, Peter ^a,b   Warde, Padraig ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; DISEASE SEVERITY; EDITORIAL; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RISK FACTOR; SEMINOMA; THERAPY EFFECT;

ADULT; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; HEART DISEASES; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; ORCHIECTOMY; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; SEMINOMA; TESTICULAR NEOPLASMS; TIME FACTORS;

EID: 79551702823     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq535     Document Type: Editorial

References (20)

1. Manecksha RP, Fitzpatrick JM. Epidemiology of testicular cancer. BJU Int. 2009;104(9, pt B):1329-1333.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
3. Mead GM, Fossa SD, Oliver RTD, et al.; for the MRC/EORTC Seminoma Trial Collaborators. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103(3):241-249.
4. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354-1365. (Pubitemid 41487803)
5. Van den Belt-Dusebout AW, De Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25(28):4370-4378. (Pubitemid 350013842)
6. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-1523. (Pubitemid 46594104)
7. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol. 2004;22(4):640-647. (Pubitemid 41095067)
8. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-4657.
9. Aparicio J, Germa JR, Del Muro XG, et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol. 2005;23(34):8717-8723. (Pubitemid 46211516)
10. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer. 2002;38(1):11-16. (Pubitemid 34031819)
11. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. Apmis. 2003;111(1):76-83; discussion 83-75.
12. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol. 2002;42(6):553-562; discussion 562-553.
13. Horwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer. 1992;65(5):775-778.
14. Tyldesley S, Voduc D, McKenzie M, Duncan G, Liu M, Wu D. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology. 2006;67(3):594-598. (Pubitemid 43343550)
15. Von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis [see comment]. Eur J Cancer. 1993;29A(14):1931-1934. (Pubitemid 23324346)
16. Leung E, Chung P, Panzarella, et al. Total treatment Burden in stage I seminoma patients. J Clin Oncol. 2010;28(15S):350s.
17. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448-4452. (Pubitemid 35334756)
18. O'Malley ME, Chung P, Haider M, et al. Comparison of low dose with standard dose abdominal/pelvic multidetector CT in patients with stage 1 testicular cancer under surveillance. Eur Radiol. 2010;(7):1624-1630.
19. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478-496.
20. Wood L, Kollmannsberger C, Jewett M, et al. Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J. 2010;4(2):e19-e38.